Please provide your email address to receive an email when new articles are posted on . XEN1101 is a novel small-molecule selective Kv7.2/Kv7.3 potassium channel opener. A 25 mg dose of XEN1101 ...

Focal-onset seizures (FOSs) are the most common type of seizure experienced by epileptic individuals. A recent randomized control trial published in JAMA Neurology evaluated the effect of a novel ...

Epilepsy is a common neurological disorder that affects millions of people worldwide. Characterized primarily by seizures, epilepsy can present in a variety of ways depending on the individual and the ...

Epilepsy presents differently in each person. The condition has a range of symptoms that varies. Convulsions can be one sign of epilepsy. However, people often experience epilepsy without ever having ...

“It’s all about the brain,” said Jennifer DeWolfe, D.O., professor in the UAB Department of Neurology. “Seizure manifestations are stereotyped, so the same symptoms occur with each seizure that ...

Long-term, real-world evidence demonstrates early and lasting outcomes of adjunctive VNS Therapy on severe focal seizures The CORE-VNS 36-month data analysis reaffirms the effectiveness of VNS Therapy ...

If you have a first seizure as an adult, it could be an indication of epilepsy, or it may be an isolated episode. Causes in adults include a stroke, head trauma, alcohol withdrawal, brain tumor, or ...

A new drug candidate has shown impressive results in a mid-stage clinical trial for drug-resistant epilepsy, raising hopes for patients who continue to suffer seizures despite being on multiple ...

About 60-70% of focal epilepsy patients achieve seizure control with first-line antiseizure medications (ASMs). Lamotrigine and levetiracetam demonstrate high efficacy and tolerability for seizure ...

Longitudinal data suggested that treatment-resistant focal epilepsy may improve over time. Nearly 70% had reduced seizure frequency and some patients achieved seizure freedom. Improvement was not ...